Evidence-based·Updated November 19, 2026·How we grade evidence

Naltrexone (Low-Dose Naltrexone)

MedicationOpioid blocker (prescription)

At its labeled doses, naltrexone modestly helps people with alcohol use disorder drink less and, as a monthly injection after detox, helps people with opioid use disorder stay opioid-free. Low-dose naltrexone is an off-label use: the two largest fibromyalgia trials found no benefit over placebo, and evidence for Crohn's disease, multiple sclerosis, long COVID and depression is small, low certainty or negative.

Taking Naltrexone (Low-Dose Naltrexone) with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with alcohol use disorder, or with opioid use disorder who have completed detox, whose prescriber recommends naltrexone as part of a treatment program

Common dosing range

Your prescriber sets the dose. Labeled doses: 50 mg tablets once daily (for opioid blockade, starting at 25 mg), or Vivitrol 380 mg injected every 4 weeks. Low-dose use (1 to 6 mg a day) is off-label

When to expect effects

Opioid blocking starts with the first effective dose; Vivitrol blocks opioids for about 28 days per injection. Drinking outcomes were measured over 12 weeks to 6 months

Watch out for

You must be opioid-free for at least 7 to 10 days before starting, or severe withdrawal can occur. After stopping, missing a dose or near the end of a Vivitrol month, a previously tolerated opioid dose can be fatal. Contraindicated with opioid pain medicines. The current labels carry no boxed warning, but warn about liver injury, depression and suicidal thoughts, and (Vivitrol) severe injection-site reactions

What is it

Naltrexone is a prescription opioid blocker (opioid antagonist). It comes as 50 mg naltrexone hydrochloride tablets, approved for alcohol dependence and to block the effects of opioids, and as Vivitrol, a monthly 380 mg injection into the buttock muscle given by a healthcare provider, approved for alcohol dependence in people who can stop drinking before starting and to prevent relapse to opioid dependence after detox. Both labels say it should be used as part of a broader treatment plan for addiction, and the Vivitrol label specifies a program that includes psychosocial support. Naltrexone is also one of the two ingredients in Contrave, a weight-management tablet with bupropion, which this page does not cover. "Low-dose naltrexone" (LDN) means taking roughly 1 to 6 mg a day, a small fraction of the labeled 50 mg dose, for conditions such as fibromyalgia, Crohn's disease or multiple sclerosis. That is an off-label use: no FDA-approved naltrexone product comes in these strengths or is approved for these conditions.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have alcohol use disorder and want a medicine to help cut down or stay sober, with your prescriber and a support program
You have completed opioid detox, have been opioid-free for at least 7 to 10 days, and want a non-opioid option to prevent relapse
You are considering low-dose naltrexone and want to weigh the mixed trial results with a doctor who knows your condition

Probably skip if…

You take opioid pain medicines or are physically dependent on opioids, including methadone or buprenorphine (contraindicated)
You are in acute opioid withdrawal or have a positive opioid urine test
You have acute hepatitis or significant liver problems, which your prescriber needs to assess first
You expect low-dose naltrexone to reliably relieve fibromyalgia pain: the two largest trials found no difference from placebo

Evidence at a glance

alcohol use disorder (oral tablets)

Good Evidence
Effect
Modest; 1 in 12 people treated avoided a return to heavy drinking
Best fit
Adults with alcohol use disorder who have stopped or are trying to stop drinking, with counseling or medical follow-up
Time
Trials of 12 weeks or longer

alcohol use disorder (Vivitrol injection)

Good Evidence
Effect
Moderate; 25% fewer heavy drinking days with 380 mg
Best fit
Adults who can stop drinking before the first injection, as the label requires
Time
Measured over 6 months

preventing relapse in opioid use disorder (Vivitrol injection)

Good Evidence
Effect
Large versus placebo; similar to buprenorphine-naloxone once started
Best fit
Adults who have completed detox and can stay opioid-free for 7 to 10 days before the first injection
Time
Measured over 24 weeks

fibromyalgia (low-dose naltrexone, off-label)

Good Evidence
Effect
None significant in the two largest parallel trials
Best fit
Not established
Time
Measured at 12 weeks to 12 months

active Crohn's disease (low-dose naltrexone, off-label)

Limited Evidence
Effect
Uncertain; better response rates but no significant difference in remission in one small trial
Best fit
Adults with active Crohn's disease in a specialist's care
Time
Measured at 8 to 12 weeks

quality of life in multiple sclerosis (low-dose naltrexone, off-label)

Limited Evidence
Effect
Inconsistent; small improvements in one trial, none in another
Best fit
Adults with MS, alongside disease-modifying treatment
Time
Measured over 8 to 17 weeks

depression, added to an antidepressant (low-dose naltrexone, off-label)

Limited Evidence
Effect
None in the larger trial
Best fit
Not established
Time
Measured at 3 to 12 weeks

long COVID (low-dose naltrexone, off-label)

Mixed Evidence
Effect
Unknown; improvements in uncontrolled studies only
Best fit
Not established
Time
Not established

Evidence for 8 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

alcohol use disorder (oral tablets)

Disease adjunct
Good Evidence

A 2014 meta-analysis of 122 trials in adults with alcohol use disorder, including 53 trials of naltrexone (9,140 participants), found that oral naltrexone 50 mg a day lowered the return to heavy drinking (1 extra person avoided heavy drinking for every 12 treated) and the return to any drinking (1 in 20, with a wide confidence interval). It did about as well as acamprosate when they were compared directly. In the COMBINE trial of 1,383 recently abstinent US adults, naltrexone 100 mg a day with medical management for 16 weeks increased days abstinent (80.6% vs 75.1% with placebo) and lowered the risk of a heavy drinking day (hazard ratio 0.72); differences were no longer significant a year after treatment.

Effect size
Modest; 1 in 12 people treated avoided a return to heavy drinking
Time to effect
Trials of 12 weeks or longer
Best fit
Adults with alcohol use disorder who have stopped or are trying to stop drinking, with counseling or medical follow-up
Less likely
People who still take opioids, for whom it is contraindicated

Bottom line: Naltrexone tablets modestly reduce heavy drinking when added to support.

alcohol use disorder (Vivitrol injection)

Disease adjunct
Good Evidence

In a 6-month double-blind trial at 24 US sites, 624 actively drinking alcohol-dependent adults received monthly injections of 380 mg or 190 mg long-acting naltrexone or placebo, plus low-intensity counseling. The 380 mg dose cut the rate of heavy drinking days by 25% compared with placebo; the 190 mg dose by 17%, which was not statistically significant. Effects were larger in men and in people who had stopped drinking before the first injection. The label adds that in the 8% who had stopped drinking the week before the first injection, drinking days, heavy drinking days and abstinence improved, and that these effects were not evident in the 92% who were still drinking at the start.

Effect size
Moderate; 25% fewer heavy drinking days with 380 mg
Time to effect
Measured over 6 months
Best fit
Adults who can stop drinking before the first injection, as the label requires
Less likely
People who are actively drinking when treatment starts

Bottom line: Monthly Vivitrol reduces heavy drinking, mainly in people who have already stopped before starting.

preventing relapse in opioid use disorder (Vivitrol injection)

Disease adjunct
Good Evidence

In a double-blind trial in Russia, 250 adults who had completed detox and been opioid-free for at least 7 days received Vivitrol 380 mg or placebo monthly for 24 weeks with counseling. Confirmed opioid-free weeks were 90.0% versus 35.0% (median), and craving fell. That trial was funded by Alkermes, the maker of Vivitrol. In the US X:BOT trial of 570 adults, starting Vivitrol was harder than starting buprenorphine-naloxone (72% vs 94% got their first dose), so relapse was more common overall (65% vs 57%); among people who did start, relapse rates were similar.

Effect size
Large versus placebo; similar to buprenorphine-naloxone once started
Time to effect
Measured over 24 weeks
Best fit
Adults who have completed detox and can stay opioid-free for 7 to 10 days before the first injection
Less likely
People who cannot complete detox, for whom starting is often unsuccessful

Bottom line: Once started after detox, monthly Vivitrol helps people stay off opioids about as well as buprenorphine.

fibromyalgia (low-dose naltrexone, off-label)

No benefit found
Good Evidence

Off-label use at doses far below the labeled 50 mg. In a 12-week double-blind trial in Denmark, 99 women aged 18 to 64 with fibromyalgia took 6 mg a day or placebo: pain fell by 1.3 versus 0.9 points on a 0 to 10 scale, a difference that was not statistically significant. In the 12-month INNOVA trial at one center in Spain, 98 women took 4.5 mg a day or placebo, and pain at 3 months did not improve more than with placebo (minus 0.33 vs minus 0.64 points). A 2025 meta-analysis of 8 studies found no significant difference from placebo. An earlier crossover trial in 31 women reported more pain reduction with 4.5 mg (28.8% vs 18.0%).

Effect size
None significant in the two largest parallel trials
Time to effect
Measured at 12 weeks to 12 months
Best fit
Not established
Less likely
Women with fibromyalgia, the group studied in the largest trials

Bottom line: Off-label low-dose naltrexone did not relieve fibromyalgia pain better than placebo in the largest trials.

Evidence is mixed

Earlier small crossover trials, including one in 31 women, reported less pain with 4.5 mg, but larger parallel-group trials and a 2025 meta-analysis did not confirm a difference from placebo.

active Crohn's disease (low-dose naltrexone, off-label)

Disease adjunct
Limited Evidence

Off-label use. A 2018 Cochrane review found 2 small placebo-controlled trials (46 participants). In 34 adults given 4.5 mg a day for 12 weeks, remission was 30% versus 18% (not statistically significant), while a 70-point clinical response (83% vs 38%) and endoscopic response (72% vs 25%) were more common. A trial in 12 children mainly tested safety. The review rated the certainty of evidence as low and said there is not enough evidence for firm conclusions.

Effect size
Uncertain; better response rates but no significant difference in remission in one small trial
Time to effect
Measured at 8 to 12 weeks
Best fit
Adults with active Crohn's disease in a specialist's care
Less likely
Anyone using it in place of proven Crohn's treatment

Bottom line: Too little evidence to know whether off-label low-dose naltrexone helps Crohn's disease.

quality of life in multiple sclerosis (low-dose naltrexone, off-label)

Disease adjunct
Limited Evidence

Off-label use. In a US crossover trial of 80 people with multiple sclerosis (60 completed), 4.5 mg nightly for 8 weeks improved several mental health quality of life scores, but dropouts and data errors reduced the trial's power. In a 17-week trial at two universities with 96 people with relapsing-remitting or secondary progressive MS, quality of life measures did not differ from placebo. Neither trial measured relapses or disability progression as a main outcome.

Effect size
Inconsistent; small improvements in one trial, none in another
Time to effect
Measured over 8 to 17 weeks
Best fit
Adults with MS, alongside disease-modifying treatment
Less likely
Anyone using it instead of disease-modifying treatment, which was not studied

Bottom line: Two small trials disagree; off-label low-dose naltrexone is unproven for MS.

depression, added to an antidepressant (low-dose naltrexone, off-label)

No benefit found
Limited Evidence

Off-label use. In a 2026 double-blind trial, 37 people with moderate major depression already taking an antidepressant received up to 4.5 mg a day or placebo for 12 weeks. Depression scores fell by 10.5 versus 9.8 points, with no difference between groups, and an inflammation marker (hsCRP) did not change. A 2017 pilot trial of 12 people taking dopamine-acting antidepressant regimens found better scores on some scales with 1 mg twice daily for 3 weeks, but not on its main measure.

Effect size
None in the larger trial
Time to effect
Measured at 3 to 12 weeks
Best fit
Not established
Less likely
Adults with moderate depression on antidepressants, the group studied

Bottom line: Off-label low-dose naltrexone did not ease depression in the larger of two small trials.

Evidence is mixed

A 12-person pilot trial reported improvement on some depression scales but not on its main measure.

long COVID (low-dose naltrexone, off-label)

Disease adjunct
Mixed Evidence

Off-label use. A 2026 systematic review searched through May 2026 and found no randomized controlled trials of low-dose naltrexone in long COVID. Four small before-and-after studies (155 people in the USA and Ireland, 1 to 6 mg a day) reported less fatigue, brain fog and pain, but without a placebo group these changes cannot be separated from natural recovery or expectation, and the authors rated the certainty of evidence as low.

Effect size
Unknown; improvements in uncontrolled studies only
Time to effect
Not established
Best fit
Not established
Less likely
Not established

Bottom line: No randomized trial yet shows whether off-label low-dose naltrexone helps long COVID.

How it works

Naltrexone attaches to opioid receptors in the brain and body and blocks them, so opioid drugs have little effect while it is active. In alcohol use disorder it is thought to reduce the rewarding effect of drinking and the urge to drink. Because it blocks opioids, a person who is still physically dependent on opioids can go into sudden, severe withdrawal if they take it, which is why the labels recommend being opioid-free for at least 7 to 10 days first. After it wears off, tolerance to opioids is lower than before, which raises the risk of a fatal overdose. The idea behind low-dose naltrexone is different and less proven. Researchers have proposed that a small dose blocks opioid receptors only briefly, which might lead the body to raise its own endorphins, and that it may calm immune cells in the nervous system. These ideas come mainly from laboratory work; human trials have given mixed results.

How to take it

1. Typical dose
Your prescriber sets the dose. Tablets (50 mg): for alcohol dependence, 50 mg once daily, the dose used for up to 12 weeks in the placebo-controlled trials; for opioid blockade, start with 25 mg and, if no withdrawal signs occur, 50 mg a day. Vivitrol: 380 mg injected deep into the buttock muscle by a healthcare provider every 4 weeks or once a month, alternating sides; it must not be self-injected. Both need an opioid-free period of at least 7 to 10 days before the first dose.
2. Higher studied dose
The COMBINE trial used oral naltrexone 100 mg a day for 16 weeks. The tablet label says placebo-controlled studies of up to 300 mg a day caused liver cell injury in a substantial proportion of people. Low-dose trials (off-label) used 4.5 mg a day (fibromyalgia, Crohn's disease, multiple sclerosis), 6 mg a day (fibromyalgia) and 1 mg twice daily (depression); these are research doses, not recommendations.
3. Timing
Tablets once a day as directed; Vivitrol every 4 weeks. If a Vivitrol dose is missed, the label says to get the next one as soon as possible.
4. With food
The labels give no food requirement for the tablets; follow your prescriber's or pharmacist's directions
5. Split dosing
Not part of labeled dosing. Some low-dose trials split doses (for example 1 mg twice daily), which is off-label
6. How long to try
Your prescriber decides; it works only as part of a treatment plan. Do not stop on your own, and know that stopping lowers your opioid tolerance

What to track

Any opioid use in the past 7 to 10 days (people coming off methadone or buprenorphine may be vulnerable to withdrawal for up to 2 weeks), which must be disclosed before starting
Signs of opioid overdose in yourself or others, especially after stopping or near the end of a Vivitrol month; ask about having naloxone or nalmefene on hand
Belly pain lasting more than a few days, dark urine, pale stools or yellow eyes (possible liver injury)
Low mood or thoughts of suicide (tell your provider promptly)
For Vivitrol: injection-site pain, hard lumps, blisters, open wounds or swelling that gets worse

Bottom line: Your prescriber sets the dose: 50 mg tablets daily or a 380 mg injection monthly after being opioid-free; low-dose use is off-label.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Nausea, vomiting, diarrhea, belly pain and loss of appetiteHeadache, dizziness, tiredness, trouble sleeping and anxietyWith Vivitrol: pain, tenderness, hardness or swelling where it was injectedIn low-dose fibromyalgia trials, side effects were about as common as with placebo (84% vs 86% in one trial, 68.8% vs 72% in another)

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the Vivitrol label says the available data from published case series are not enough to identify a drug-related risk of major birth defects, miscarriage or other harm, and that untreated opioid addiction and alcohol use in pregnancy carry their own serious risks to the baby. In animal studies, oral naltrexone increased early pregnancy loss in rats and rabbits but did not cause malformations. The tablet label says it should be used in pregnancy only if the potential benefit justifies the potential risk. Breastfeeding: the tablet label says it is unknown whether naltrexone passes into human milk and advises caution. The newer Vivitrol label says naltrexone and its main breakdown product pass into human milk, with no data on effects on the baby or on milk supply, and that the benefits of breastfeeding should be weighed against the mother's need for treatment. Anyone pregnant, planning pregnancy or breastfeeding should discuss it with their prescriber.

Interactions

Opioid pain medicines and opioid-containing cough, cold and antidiarrheal productsCritical

Naltrexone is contraindicated in people taking opioid pain medicines and blocks the effect of opioid-containing cough, cold and antidiarrheal products. Taking opioids while on it can cause withdrawal, and taking large amounts to overcome the block can cause fatal overdose. For emergency pain, the label suggests options such as regional analgesia (numbing a region of the body) or non-opioid pain relievers, and if opioids are needed the dose may be higher and breathing effects deeper and longer. Tell every prescriber and your pharmacist that you take naltrexone.

Methadone and buprenorphine (opioid treatment medicines)Critical

The tablet label says naltrexone is contraindicated in people currently maintained on methadone or buprenorphine, because it can trigger severe withdrawal. People switching from these medicines may be vulnerable to withdrawal for as long as 2 weeks, so the switch is planned by the prescriber.

DisulfiramModerate

The tablet label says the safety and effectiveness of using naltrexone with disulfiram are unknown, and that combining two medicines that can harm the liver is not ordinarily recommended unless the likely benefits outweigh the risks. Your prescriber decides whether the combination is appropriate and how to monitor your liver.

ThioridazineModerate

The tablet label reports lethargy and sleepiness after doses of naltrexone taken with the antipsychotic thioridazine. Tell your prescriber if you take it.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Naltrexone hydrochloride 50 mg tablets dispensed by a licensed pharmacy on your own prescription, or Vivitrol given by a healthcare provider
For Vivitrol: the 380 mg kit with its own diluent and needles, injected into the buttock muscle
A Medication Guide that explains the overdose risk after stopping, the opioid-free period before starting and the liver warning
For low-dose use: the prescriber has explained that it is off-label and how the low-strength product was prepared

Be skeptical of…

"LDN cures" or "reverses" autoimmune disease, fibromyalgia, MS, Crohn's disease or long COVID: trials are small, low certainty or negative
"FDA-approved low-dose naltrexone": no FDA-approved naltrexone product comes in low strengths or is approved for these conditions
"Naltrexone makes it safe to keep using opioids": the block can be overcome, which can be fatal
Online sellers offering naltrexone without a prescription
"Take it while still using opioids to detox faster": this can cause severe precipitated withdrawal

Frequently asked questions

What is low-dose naltrexone, and is it approved?⌄

Low-dose naltrexone (LDN) means taking about 1 to 6 mg a day, far below the labeled 50 mg tablet dose. It is an off-label use: no FDA-approved naltrexone product comes in these strengths or is approved for fibromyalgia, Crohn's disease, MS, long COVID or other conditions it is promoted for. A prescriber may still choose it, but the evidence is limited.

Does low-dose naltrexone work for fibromyalgia?⌄

The best trials say probably not. In two parallel trials of about 100 women each (6 mg and 4.5 mg a day), pain did not improve more than with placebo, and a 2025 meta-analysis found no significant difference. Earlier small crossover studies were more positive. Side effects were about as common as with placebo.

What is the difference between Vivitrol and naltrexone tablets?⌄

Both contain naltrexone. Tablets are 50 mg taken by mouth once a day, approved for alcohol dependence and to block opioids. Vivitrol is a 380 mg injection given by a healthcare provider every 4 weeks, approved for alcohol dependence in people who can stop drinking before starting and to prevent relapse after opioid detox. The monthly injection avoids the need to remember a daily pill.

Can I take opioid pain medicine while on naltrexone?⌄

Naltrexone is contraindicated with opioid pain medicines: it blocks them and can cause withdrawal, and trying to overcome the block with large doses can be fatal. Tell every doctor, dentist and pharmacist you take naltrexone, and carry information about it. Do not stop it on your own before a procedure; your prescriber plans that.

Can I take naltrexone with my supplements?⌄

Our interaction database has no supplement pairs for naltrexone yet, and the tablet label says interaction studies with drugs other than opioids have not been done. Opioid-containing products are the main concern, so check any cough, cold or diarrhea remedy and any herbal product with your pharmacist before using it.

Why is overdose a risk after stopping naltrexone?⌄

While you take naltrexone, your body loses some of its tolerance to opioids. When it wears off, after you stop, miss a dose or reach the end of a Vivitrol month, an opioid dose you used to tolerate can stop your breathing. The labels advise talking with your provider about having an overdose reversal medicine such as naloxone available.

References by claim

alcohol use disorder (oral tablets)

Jonas et al., 2014 · PubMed (2014) link

Anton et al., 2006 · PubMed (2006) link

alcohol use disorder (Vivitrol injection)

Garbutt et al., 2005 · PubMed (2005) link

preventing relapse in opioid use disorder (Vivitrol injection)

Krupitsky et al., 2011 · PubMed (2011) link

Lee et al., 2018 · PMC (2018) link

fibromyalgia (low-dose naltrexone, off-label)

Due Bruun et al., 2024 · PubMed (2024) link

Rodríguez-Freire et al., 2026 · PMC (2026) link

Ologunowa et al., 2025 · PubMed (2025) link

Younger et al., 2013 · PubMed (2013) link

active Crohn's disease (low-dose naltrexone, off-label)

Parker et al., 2018 · PMC (2018) link

quality of life in multiple sclerosis (low-dose naltrexone, off-label)

Cree et al., 2010 · PubMed (2010) link

Sharafaddinzadeh et al., 2010 · PubMed (2010) link

long COVID (low-dose naltrexone, off-label)

Byambasuren et al., 2026 · PMC (2026) link

depression, added to an antidepressant (low-dose naltrexone, off-label)

Moloney et al., 2026 · PMC (2026) link

Mischoulon et al., 2017 · PubMed (2017) link

Safety

Vivitrol (naltrexone for extended-release injectable suspension) prescribing information · DailyMed (FDA label) link

Naltrexone hydrochloride tablets USP 50 mg prescribing information · DailyMed (FDA label) link

Track Naltrexone (Low-Dose Naltrexone) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.